Biodesix to Participate in Three Investor Conferences in November

Rhea-AI Summary

Biodesix (Nasdaq: BDSX), a diagnostic solutions company specializing in lung disease, has announced its participation in three upcoming investor conferences in New York this November. CEO Scott Hutton and CFO Robin Cowie will attend the Craig-Hallum Alpha Select Conference on November 19, the Wolfe Research Healthcare Conference on November 20, and the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 21.

The company will deliver a presentation at the Canaccord event at 1:00 PM ET, which will be available via webcast on the Biodesix website's Investors section under 'News & Events'.

News Market Reaction

+3.13%

1 alert

+3.13% News Effect

On the day this news was published, BDSX gained 3.13%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

Craig-Hallum 15^th Annual Alpha Select Conference
1x1 Meetings
Date: Tuesday, November 19, 2024
Location: New York, NY

Wolfe Research Healthcare Conference 2024
1x1 Meetings
Date: Wednesday, November 20, 2024
Location: New York, NY

Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum
Presentation and 1x1 Meetings
Presentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ET
Location: New York, NY

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.

About Biodesix

Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.

Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.

Contacts:

Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285

Investors:
Chris Brinzey
chris.brinzey@westwicke.com
1-339-970-2843

FAQ

When is Biodesix (BDSX) presenting at the Canaccord Genuity Conference in November 2024?

Biodesix will present at the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on Thursday, November 21, 2024, at 1:00 PM ET in New York.

Which investor conferences is Biodesix (BDSX) attending in November 2024?

Biodesix is attending three conferences: Craig-Hallum Alpha Select Conference (Nov 19), Wolfe Research Healthcare Conference (Nov 20), and Canaccord Genuity Medtech Forum (Nov 21), all in New York.

How can investors watch Biodesix's (BDSX) Canaccord conference presentation?

Investors can watch the presentation via webcast live or replay through the 'News & Events' section in the Investors area of Biodesix's website at biodesix.com.